Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00373711|
Recruitment Status : Withdrawn (Abandoned)
First Posted : September 8, 2006
Last Update Posted : April 11, 2011
|Condition or disease||Intervention/treatment|
|Thyroid Cancer||Drug: Iodine-124 Drug: Iodine-123 Drug: F-18 FDG|
The management of thyroid cancer patients with suspicion of recurrent disease based on rising/detectable levels of thyroglobulin (Tg) involves imaging with iodine-123 whole body scintigraphy (I-123 WBS) and F-18 FDG PET/CT. However, the disease is not always detected. The use of another iodine isotope (I-124) with positron emitting characteristics for PET/CT may allow better identification of recurrent disease, thus allowing for more patients to be treated with I-131 as a curative attempt.
Conducting this study we hope to find whether I-124 PET/CT allows for detection of more lesions in patients with suspected recurrent thyroid cancer than the current standard of care represented by I-123 WBS and F-18 FDG PET/CT.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Comparison of I-124 PET/CT, F-18 FDG PET/CT and I-123 Whole Body Scintigraphy for Recurrent Thyroid Cancer Detection|
|Study Start Date :||May 2007|
- Fludeoxyglucose (18 F)
- fluorodeoxyglucose (18 F)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00373711
|Principal Investigator:||Andrei Iagaru||Stanford University|
|Principal Investigator:||Iain Ross McDougall||Stanford University|